Nasdaq-listed biotech company Oculis announced the pricing of an underwritten offering of 5,000,000 of its ordinary shares at a price of $20.00 per share, for total gross proceeds of $100 million. Proceeds will be used to advance and accelerate its clinical development pipeline, particularly the development of its novel neuroprotective clinical candidate Privosegtor (OCS-05)..

纳斯达克上市的生物技术公司Oculis宣布，将以每股20.00美元的价格承销其500万股普通股，总收益为1亿美元。收益将用于推进和加速其临床开发流程，特别是其新型神经保护临床候选药物Privosegtor（OCS-05）的开发。。

This Offering follows the release of recent groundbreaking data from the Phase 2 ACUITY trial of OCS-05 (Privosegtor), which has the potential to be the first neuroprotective treatment in ophthalmology, in patients with acute optic neuritis. Data showed OCS-05 met the primary endpoint of safety, in addition to key secondary endpoints that highlighted its neuroprotective structural benefits and the ability to improve visual function in this disease area, with potential to expand across multiple ophthalmic and neurological conditions, including glaucoma..

OCS-05（Privosegtor）第二阶段视力试验最近发布了开创性的数据，该试验有可能成为急性视神经炎患者眼科的第一种神经保护治疗方法。数据显示，OCS-05符合安全性的主要终点，此外还有关键的次要终点，突出了其神经保护结构的益处和改善该疾病领域视觉功能的能力，并有可能扩展到多种眼科和神经系统疾病，包括青光眼。。

Oculis

奥库里斯

is a global biopharmaceutical company purposefully driven to save sight and improve eye care. Oculis’ highly differentiated pipeline of multiple innovative product candidates in development includes: OCS-01, a topical eye drop candidate for diabetic macular edema; Privosegtor (OCS-05) and Licaminlimab (OCS-02), a topical biologic anti-TNFα eye drop candidate for dry eye disease..

是一家全球性生物制药公司，旨在挽救视力和改善眼部护理。Oculis正在开发的多种创新产品候选产品的高度分化渠道包括：OCS-01，一种用于糖尿病性黄斑水肿的局部滴眼剂候选产品；Privosegtor（OCS-05）和Licaminlimab（OCS-02），一种用于干眼症的局部生物抗TNFα滴眼剂候选药物。。

Headquartered in Switzerland with operations in the U.S. and Iceland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors.

Oculis总部位于瑞士，在美国和冰岛有业务，由经验丰富的管理团队领导，拥有成功的业绩记录，并得到领先的国际医疗保健投资者的支持。

0

0

Comments

评论

Back to all news

返回所有新闻

Please

求你了

login

登录名

or

或

sign up

注册

to comment.

发表评论。

Commenting guidelines

评论指南

Send

发送